Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has received a consensus recommendation of "Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $35.71.

DAWN has been the topic of a number of recent analyst reports. TD Cowen raised shares of Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating on the stock in a research report on Monday. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, Needham & Company LLC reissued a "buy" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock traded up $0.05 on Tuesday, hitting $12.26. 601,538 shares of the stock traded hands, compared to its average volume of 1,015,048. The firm's 50-day moving average price is $12.47 and its two-hundred day moving average price is $13.54. The stock has a market capitalization of $1.24 billion, a PE ratio of -11.90 and a beta of -1.46. Day One Biopharmaceuticals has a twelve month low of $11.13 and a twelve month high of $18.07.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the sale, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.40% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently made changes to their positions in DAWN. R Squared Ltd purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after purchasing an additional 1,002 shares during the last quarter. Quest Partners LLC increased its stake in Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company's stock valued at $108,000 after purchasing an additional 7,668 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock valued at $135,000 after purchasing an additional 9,603 shares during the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at approximately $143,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.